Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2012 Oct 25;13(1):48–54. doi: 10.1016/j.clml.2012.07.009

Figure 2. Survey Respondents’ Most Critical Time Point to Evaluate Response to First-Line Tyrosine Kinase Inhibitor Therapy, Based on the Question From Figure 1 (Question 14).

Figure 2

Abbreviations: CCyR = complete cytogenetic response; CHR = complete hematologic response; CMR = complete molecular response; MMR = major molecular response.